WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of FASENRA ® (benralizumab) in a pre-filled, ...

The FDA has expanded the approval of Fasenra (benralizumab; AstraZeneca) to include self-administration with the Fasenra Pen, a prefilled, single-use autoinjector. The Food and Drug Administration ...

FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca ...

In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.

AstraZeneca received approval from FDA for Fasenra Pen, a pre-fillled auto-injector pen that allows for self-administration of its asthma biologic therapy, Fasenra (benralizumab). FDA has approved ...

Fasenra is now the only respiratory biologic that offers the choice of administration at home or in a doctor's office with eight-week maintenance dosing The approval is supported by data from the ...

Fasenra is a brand-name solution given as a subcutaneous injection. Doctors prescribe the drug for certain inflammatory conditions. Fasenra contains the active ingredient benralizumab and is a type of ...

Fasenra receives positive EU CHMP opinion for self-administrationand the new Fasenra pen, a pre-filled, single-use auto-injector AstraZeneca today announced that the European Medicines Agency's ...

Fasenra (benralizumab) is a prescription drug that’s used to treat conditions such as eosinophilic asthma. Fasenra is given as an injection under your skin. This drug should not be used in certain ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...

Back in mid-2018, AstraZeneca’s Fasenra hit a speed bump as England’s drug cost watchdog recommended it only when GlaxoSmithKline’s rival asthma drug Nucala wasn’t appropriate. But now, the AZ drug is ...